Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.

ABSTRACT:

Background and objectives

Patients receiving hemodialysis are at risk of cardiovascular events. A novel blood test (T₅₀ test) determines the individual calcification propensity of blood.

Design, setting, participants, & measurements

T₅₀ was determined in 2785 baseline serum samples of patients receiving hemodialysis enrolled in the Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial and the T₅₀ results were related to patient outcomes.

Results

Serum albumin, bicarbonate, HDL cholesterol, and creatinine were the main factors positively/directly and phosphate was the main factor negatively/inversely associated with T₅₀. The primary composite end point (all-cause mortality, myocardial infarction [MI],

SUBMITTER: Pasch A 

PROVIDER: S-EPMC5293330 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature